Incorporation of Vitamin K Into Uremic Lipoproteins
- Conditions
- Vitamin K Deficiency
- Interventions
- Drug: Vitamin K supplement
- Registration Number
- NCT05360342
- Lead Sponsor
- RWTH Aachen University
- Brief Summary
Chronic kidney disease (CKD) patients have an increased cardiovascular risk with corresponding cardiovascular calcifications. CKD patients exhibit a functional vitamin K deficiency. Calcification can be prevented by vitamin K intake. The aim of this study is to investigate the cause for the vitamin K deficiency beyond a diminished dietary vitamin K uptake.
- Detailed Description
This study is a monocentric, 1-armed interventional trial. Participants will be recruited at the University Hospital of the RWTH Aachen.
We will analyse serially collected serum from 10 dialysis patients, after ingestion of a single vitamin K supplement, compared to healthy controls. Lipoprotein fractions will be isolated and the corresponding vitamin K contents will be measured by chromatography.
The vitamin K supplement contains 3 subforms of vitamin K: vitamin K1 (1000µg), menaquinone-4 (1000µg) and menaquinone-7 (200µg).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Vitamin K supplement Vitamin K supplement Administration of a single dose vitamin K
- Primary Outcome Measures
Name Time Method Vitamin K content in lipoproteins 1 year Assessment of vitamin K incorporation into lipoproteins
- Secondary Outcome Measures
Name Time Method PIVKA-II levels 1 year PIVKA-II in serum as assessed by ELISA
Trial Locations
- Locations (1)
RWTH Aachen University
🇩🇪Aachen, Germany